Brian Robert Mcmanus, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 928 Dixie Hwy, Rossford, OH 43460 Phone: 419-666-5299 |
News Archive
Funxional Therapeutics Ltd (Funxional) has announced today the successful completion of the Phase I programme of its novel anti-inflammatory, FX125L, an orally available small molecule that belongs to a new therapeutic class named Broad Spectrum Chemokine Inhibitors (BSCIs).
People with dental caries have a reduced risk for developing head and neck squamous cell carcinoma, a large case-control study has found.
New research published online in The FASEB Journal, suggests that carriers of the Apolipoprotein E4 allele, which is the single strongest genetic predictor of Alzheimer's disease and is associated with cognitive decline and cardiovascular disease, may have a reduced risk of cognitive decline associated with parasitic diseases.
Repligen Corporation announced today that it has filed an Investigational New Drug Application (IND) with the Food and Drug Administration (FDA) for a Phase 1 study of RG2833, a selective histone deacetylase 3 (HDAC-3) inhibitor. This is a double-blind, single ascending dose, Phase 1 study in healthy volunteers to evaluate the pharmacokinetic and safety profile of RG2833 in up to 40 subjects.
The search for new measures, or "biomarkers," to detect Alzheimer's disease (AD) before signs of memory loss appear has advanced an important step in a study by researchers at Washington University in St. Louis, MO, and the University of Pittsburgh.
› Verified 2 days ago